Compare IRTC & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRTC | FOLD |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | 2016 | 2006 |
| Metric | IRTC | FOLD |
|---|---|---|
| Price | $114.02 | $14.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $207.54 | $27.25 |
| AVG Volume (30 Days) | 569.7K | ★ 3.1M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.71 | 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $747,138,000.00 | N/A |
| Revenue This Year | $19.58 | $20.50 |
| Revenue Next Year | $15.95 | $18.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 26.24 | N/A |
| 52 Week Low | $92.52 | $5.66 |
| 52 Week High | $210.01 | $14.43 |
| Indicator | IRTC | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 70.28 |
| Support Level | $112.31 | $14.21 |
| Resistance Level | $184.04 | N/A |
| Average True Range (ATR) | 4.33 | 0.02 |
| MACD | 1.37 | -0.01 |
| Stochastic Oscillator | 27.13 | 83.33 |
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.